More Than Good Intentions: Diversity, Equity & Inclusion Requires a Program-Level, Strategic Framework
Sponsors understand the importance of diversity, equity and inclusion (DE&I) efforts and have begun to implement them in their trials, but diversity in clinical trials has yet to be achieved.
To address this gap between aspiration and execution, sponsors — as well as sites and CROs — must recognize that DE&I is not merely another project. Neither is it a series of tactics. It is a systemic, top down transformation that must be managed strategically at the program level. The DE&I strategy must be communicated and implemented across your trial sites, including referral sites. It needs to extend into the nearby community-based sources of potential patients. Most importantly, no one can execute a diversity strategy alone.
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two segments, Ethical Review and Clinical Trials Solutions (CTS), WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, visit www.wcgclinical.com.